| |NOVEMBER 20266India's 30% Anti-Cancer Drug Margin Cap: What It Means for PharmaIndia's Drug Pricing Architecture: Why the Rules Keep Expanding1038The Strategic Role of Regional Corridors in Future-Ready MedTechTransforming API & Pharma Manufacturing with Next-Gen EHS TechnologiesIndia's Role in Shaping the Future of Oncology and ImmunologyHow Deviation Trends Can Reveal Hidden Pharma Quality RisksBridging Collaboration Gaps to Boost India's Pharma DiscoveryWhy Clinical Evidence Matters More in MedTech CommercializationDr Rajiv Chhibber, Joint Forum Coordinator, Association of Indian Medical Device Industry (AiMeD)Dr Kuber Jagdale, President - API Business Unit, Emcure Pharmaceutical Business FormationPushkar Kulkarni, General Manager, Johnson & Johnson Innovative Medicine, (India & South Asia)Jayakumar A V, President (Quality), Ajanta PharmaDr Sadhna Joglekar, Senior VP & Head - Global Drug Development India, NovartisAnil Suri, Chief Commercial Officer, Sahajanand Medical TechnologiesVIVID OUTLOOKVIVID OUTLOOKVIVID OUTLOOKANALYSISVANTAGE POINTAFTERWORD522230144654THOUGHT CENTRAL
< Page 5 | Page 7 >